TABLE 2.
Relationship between cancer‐associated thromboembolism (CAT) incidence and background factors in pancreatic cancer patients
| Factor | Actual dataset | Completed dataset | ||||
|---|---|---|---|---|---|---|
| CAT+, n | CAT−, n | P value | CAT+, n | CAT−, n | P value | |
| Age, y | ||||||
| <65 | 4 | 65 | 4 | 65 | ||
| ≥65 | 9 | 119 | .50 | 9 | 119 | .50 |
| Sex | ||||||
| Male | 4 | 97 | 4 | 97 | ||
| Female | 9 | 87 | .11 | 9 | 87 | .11 |
| Disease status | ||||||
| Resectable | 1 | 5 | 1 | 5 | ||
| Locally advanced | 2 | 52 | 2 | 52 | ||
| Metastatic | 10 | 127 | .40 | 10 | 127 | .40 |
| ECOG‐PS | ||||||
| 0‐1 | 13 | 175 | 13 | 175 | ||
| 2‐3 | 0 | 9 | .53 | 0 | 9 | .53 |
| Hemoglobin, g/L | ||||||
| <100 | 2 | 18 | 2 | 18 | ||
| ≥100 | 11 | 166 | .39 | 11 | 166 | .39 |
| Hematocrit, % | ||||||
| <35 | 5 | 71 | 5 | 71 | ||
| ≥35 | 8 | 113 | .62 | 8 | 113 | .62 |
| White blood cell count, /μL | ||||||
| <11 000 | 13 | 178 | 13 | 178 | ||
| ≥11 000 | 0 | 6 | .66 | 0 | 6 | .66 |
| Platelet count, ×104/μL | ||||||
| <35 | 13 | 174 | 13 | 174 | ||
| ≥35 | 0 | 10 | .50 | 0 | 10 | .50 |
| Total protein, g/L | ||||||
| <67 | 2 | 89 | 2 | 89 | ||
| ≥67 | 11 | 95 | .019 | 11 | 95 | .019 |
| Albumin, g/L | ||||||
| <37 | 5 | 78 | 5 | 78 | ||
| ≥37 | 8 | 106 | .51 | 8 | 106 | .51 |
| Total bilirubin, mg/dL | ||||||
| <0.70 | 8 | 86 | 8 | 86 | ||
| ≥0.70 | 5 | 98 | .23 | 5 | 98 | .23 |
| Creatinine, mg/dL | ||||||
| <0.65 | 6 | 92 | 6 | 92 | ||
| ≥0.65 | 7 | 92 | .51 | 7 | 92 | .51 |
| HbA1c, % | ||||||
| <6.5 | 7 | 84 | 7.5 | 84.9 | ||
| ≥6.5 | 5 | 97 | .31 | 5.5 | 99.1 | .42 |
| T‐Cho, mg/dL | ||||||
| <178 | 2 | 91 | 2.5 | 93.4 | ||
| ≥178 | 10 | 88 | .021 | 10.5 | 90.6 | .028 |
| Triglyceride, mg/dL | ||||||
| <99 | 4 | 91 | 4 | 92.7 | ||
| ≥99 | 8 | 89 | .20 | 9 | 91.3 | .17 |
| HDL‐C, mg/dL | ||||||
| <46 | 4 | 92 | 4.3 | 93.8 | ||
| ≥46 | 8 | 88 | .19 | 8.7 | 90.2 | .21 |
| PT, % | ||||||
| <89 | 6 | 88 | 6.3 | 88 | ||
| ≥89 | 6 | 96 | .56 | 6.8 | 96 | .99 |
| APTT, s | ||||||
| <29 | 7 | 90 | 7.5 | 84.6 | ||
| ≥29 | 5 | 93 | .38 | 5.5 | 99.4 | .41 |
| Fibrinogen, mg/dL | ||||||
| <370 | 10 | 72 | 10.7 | 87.4 | ||
| ≥370 | 2 | 80 | .016 | 2.3 | 96.6 | .015 |
| D‐dimer, ng/mL | ||||||
| <1.44 | 5 | 74 | 5.4 | 78.8 | ||
| ≥1.44 | 7 | 75 | .41 | 7.6 | 105.2 | .93 |
| CA19‐9, U/mL | ||||||
| <1000 | 5 | 81 | 5 | 81 | ||
| ≥1000 | 8 | 91 | .38 | 8 | 103 | .38 |
| BMI, kg/m2 | ||||||
| <35 | 13 | 183 | 13 | 183 | ||
| ≥35 | 0 | 1 | .93 | 0 | 1 | .47 |
| Khorana score | ||||||
| 2 | 2 | 14 | 2 | 14 | ||
| 3‐5 | 11 | 170 | .29 | 11 | 170 | .29 |
| Anticancer therapy | ||||||
| GEM + nab‐PTX | 6 | 82 | .93 | 6 | 82 | .93 |
| GEM | 4 | 73 | 4 | 73 | ||
| FOLFIRINOX | 2 | 18 | 2 | 18 | ||
| Surgery | 1 | 7 | 1 | 7 | ||
| S‐1 | 0 | 2 | 0 | 2 | ||
| BSC | 0 | 2 | 0 | 2 | ||
| Tissue factor, pg/mL | ||||||
| <100 | 10 | 174 | 10 | 174 | ||
| ≥100 | 3 | 10 | .044 | 3 | 10 | .044 |
Abbreviations: APTT, activated partial thromboplastin time; BMI, body mass index; BSC, best supportive care; CA19‐9, carbohydrate antigen 19‐9; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin combination; GEM, gemcitabine; HbA1c, hemoglobin A1c; HDL‐C, high density lipoprotein cholesterol; nab‐PTX, nab‐paclitaxel; PS, performance status; PT, prothrombin time; S‐1, oral fluoropyrimidine drug; T‐Cho, total cholesterol.